Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-13T19:49:47.985Z Has data issue: false hasContentIssue false

45 - Palliative Care and Symptom Management

from PART IV - SPECIALIZED INTERVENTIONAL TECHNIQUES IN CANCER CARE

Published online by Cambridge University Press:  18 May 2010

By
Drew A. Rosielle ,
David E. Weissman  and
William S. Rilling
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Drew A. Rosielle
Affiliation:
Assistant Professor, Medicine Palliative Care Program Medical College of Wisconsin Milwaukee, WI
David E. Weissman
Affiliation:
Director, End of Life Palliative Education Resource Center Medical College of Wisconsin Milwaukee, WI
William S. Rilling
Affiliation:
Professor, Section of Vascular/Interventional Radiology Medical College of Wisconsin Milwaukee, WI
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

PALLIATIVE CARE AND COMMUNICATION WITH CANCER PATIENTS

Overview of Palliative Care

The World Health Organization defines palliative care as care [T]hat improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual (1). Medical care is focused on symptom relief and maximizing patient function, without necessarily impacting the natural history of the underlying illness. The unit of care is defined as the patients, along with their loved ones, and bereavement support is integral to its mission. Palliative care is interdisciplinary, involving not only nurses and physicians but also chaplains, psychologists, social workers, and speech, physical, occupational and other therapists. Although palliative care has historic roots in the terminal care of dying cancer patients, its scope encompasses a wide variety of patients with non-malignant diseases. These include dementia and other neurodegenerative disorders; advanced organ disease such as lung, heart, liver and kidney failure; and critically ill patients in medical, neurological, surgical and trauma critical care units (2, 3). Ideally, palliative care is provided to patients with severe illnesses early in the course of their disease, alongside disease-modifying or curative therapy. As an illness progresses, and as disease-modifying or even life-prolonging interventions become less available, a patient's entire care may become palliative focused.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 563 - 588
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. WHO definition of palliative care. Available at: http://www.who.int/cancer/palliative/definition/en. Accessed April 1, 2006.
Mosenthal, A C and Murphy, P A. Trauma care and palliative care: Time to integrate the two?J Am Coll Surg, 2003; 197: 509–516.CrossRefGoogle ScholarPubMed
Curtis, J R and Rubenfeld, G D. Improving palliative care for patients in the intensive care unit. J Palliat Med, 2005; 8: 840–854.CrossRefGoogle ScholarPubMed
Gunten, C F. Secondary and tertiary palliative care in US hospitals. JAMA, 2002; 287: 875–888.CrossRefGoogle Scholar
Himelstein, B P, Hilden, J M, Boldt, A M, et al. Pediatric palliative care. N Engl J Med, 2004; 350:1752–1762.CrossRefGoogle ScholarPubMed
Morrison, R S and Meier, D. Palliative care. N Engl J Med, 2004; 350: 2582–2590.CrossRefGoogle ScholarPubMed
Craft, P S, Burns, C M, Smith, W T, et al. Knowledge of treatment intent among patients with advanced cancer: A longitudinal study. Eur J Cancer Care, 2005; 14: 417–425.CrossRefGoogle ScholarPubMed
Schag, C C, Heinrich, R L, and Ganz, P A. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol, 1984; 2: 187–193.CrossRefGoogle ScholarPubMed
Vigano, A, Dorgan, M, Jeanette, B, et al. Survival prediction in terminal cancer patients: A systematic review of the medical literature. Palliat Med, 2000; 14: 363–374.CrossRefGoogle ScholarPubMed
Daas, N. Estimating length of survival in end-stage cancer: A review of the literature. J Pain Symptom Manage, 1995; 10: 548–555.CrossRefGoogle Scholar
Lamont, E B and Christakis, N A. Complexities in prognostication in advanced cancer. “To help them live their lives the way they want to.”JAMA, 2003; 290: 98–104.CrossRefGoogle Scholar
Maltoni, M, Pirovano, M, Scarpi, E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer, 1995; 75: 2613–2622.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Reuben, D B, Mor, V, and Hiris, J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med, 1988; 148: 1586–1591.CrossRefGoogle ScholarPubMed
Janisch, L, Mick, R, Schilsky, R L, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994; 74: 1965–1973.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Maltoni, M, Caraceni, A, Brunelli, C, et al. Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations – a study for the steering committee of the European Association for Palliative Care. J Clin Oncol, 2005; 23: 6240–6248.CrossRefGoogle Scholar
Ralson, S H, Gallacher, S J, Patel, U, et al. Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med, 1990; 112: 499–504.Google Scholar
Iwase, M, Kurachi, Y, Kakuta, S, et al. Clin Oral Investig, 2001; 5: 194–198.CrossRef
Siddiqui, F and Weissman, D E. Fast facts and concepts #151; Hypercalcemia of malignancy. February 2006. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
Khuntia, D, Brown, P, Li, J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol, 2006; 24: 1295–1304.CrossRefGoogle ScholarPubMed
Glare, P, Virik, K, Jones, M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ, 2003; 327: 195–201.CrossRefGoogle ScholarPubMed
Christakis, N A and Lamont, E B. Extent and determinants of error in doctors' prognoses in terminally ill patients: Prospective cohort study. BMJ, 2000; 320: 469–473.CrossRefGoogle ScholarPubMed
Lamont, E B, Christakis, N A. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med, 2001; 134: 1096–1105.CrossRefGoogle ScholarPubMed
Hagerty, R G, Butow, P N, Ellis, P M, et al. Communicating prognosis in cancer care: A systematic review of the literature. Ann Oncol, 2005; 16: 1005–1053.CrossRefGoogle ScholarPubMed
Randall, T C and Wearn, A M. Receiving bad news: Patients with haematological cancer reflect upon their experience. Palliat Med, 2005; 19: 594–601.CrossRefGoogle ScholarPubMed
Weissman, D E. Fast facts and concepts #13; Determining prognosis in advanced cancer, 2nd edition. July 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.Google Scholar
Ambuel, B and Weissman, D E. Fast facts and concepts #6; Delivering bad news: part 1, 2nd edition, July 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.
Ambuel, B and Weissman, D E. Fast facts and concepts #11; Delivering bad news; part 2, 2nd edition. September 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.
Weissman, D E. Decision making at a time of crisis near the end of life. JAMA, 2004; 292: 1738–1743.CrossRefGoogle Scholar
Lussier, D, Huskey, A F, and Portenoy, R K. Adjuvant analgesics in cancer pain management. The Oncologist, 2004; 9: 571–591.CrossRefGoogle ScholarPubMed
Mercadante, S and Portenoy, R K. Opioid poorly-responsive cancer pain: Part 1: Clinical considerations. J Pain Symptom Manage, 2001; 21: 144–150.CrossRefGoogle ScholarPubMed
Thomas, J R and Gunten, C F. Pain in terminally ill patients. Guidelines for pharmacological management. CNS Drugs, 2003; 17: 621–631.CrossRefGoogle ScholarPubMed
Cherny NI. Cancer pain: Principles of assessment and syndromes. In: Berger, A M, Portenoy, R K, Weissman, D E (eds). Principles and Practice of Palliative Care and Supportive Oncology, 2nd edition, pp. 3–52. New York: Lippincott Williams and Wilkins, 2002.Google Scholar
Menefee, L A and Monti, D A. Nonpharmacologic and complementary approaches to cancer pain management. J Am Osteopath Assoc, 2005; 105: S15–20.Google ScholarPubMed
Hillard, R E. Music therapy in hospice and palliative care: A review of the empirical data. eCAM, 2005; 2: 173–178.Google Scholar
Mercadante, S, Casuccio, A, Agnello, A, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage, 1999; 17: 351–356.CrossRefGoogle ScholarPubMed
Mercadante, S, Fulfaro, F, and Casuccio A, . A randomized controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: Effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer, 2002; 38: 1358–1363.CrossRefGoogle Scholar
Davis, M P, Walsh, D, Lagman, R, et al. Controversies in pharmacotherapy of pain management. Lancet Oncol, 2005; 6: 696–704.CrossRefGoogle ScholarPubMed
Leppert, W and Luczak, J. The role of tramadol in cancer pain treatment – a review. Supp Care Cancer, 2005; 13: 5–17.CrossRefGoogle ScholarPubMed
Hanks, G W, Conno, F, Cherny, N, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer, 2001; 84: 587–593.CrossRefGoogle ScholarPubMed
Gutstein, HB, Akil H. Opioid analgesics. In: Hardman, J G, Limbird, L E (eds). Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 10th edition, pp. 569–619. New York: McGraw–Hill, 2001.Google Scholar
Weissman, D E. Fast facts and concepts #71; Meperidine for pain: What's all the fuss? June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.Google Scholar
Aranoff, G M, Brennan, M J, Douglas, P D, et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med, 2005; 6: 305–314.CrossRefGoogle Scholar
Ripamonti, C, Zecca, E, and Bruera, E. An update on the clinical use of methadone for cancer pain. Pain, 1997; 70: 109–115.CrossRefGoogle ScholarPubMed
Bruera, E and Sweeney, C. Methadone use in cancer patients with pain: A review. J Palliative Med, 2002; 5: 127–138.CrossRefGoogle ScholarPubMed
Gordon, D B and Weissman, D E. Fast facts and concepts #70; PRN range analgesic orders. June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
Quigley, C. The role of opioids in cancer pain. BMJ, 2005; 331: 825–829.CrossRefGoogle ScholarPubMed
Dean, M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage, 2004; 28: 497–504.CrossRefGoogle ScholarPubMed
Paice, J A, Toy, C, and Shott, S. Barriers to cancer pain relief: Fear of tolerance and addiction. J Pain Symptom Manage, 1998; 16: 1–9.CrossRefGoogle ScholarPubMed
Sloan, P and Melzack, R. Long-term patterns of morphine dose and pain intensity among cancer patients. Hosp J, 1999; 14: 35–47.CrossRefGoogle ScholarPubMed
Collin, E, Poulain, P, Gauvain-Piquard, A, et al. Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment?Pain, 1993; 55: 319–326.CrossRefGoogle ScholarPubMed
National Cancer Institute. Substance Abuse Issues In Cancer (PDQ). Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/substanceabuse/healthprofessional. Accessed April 1, 2006.
Schug, S A, Zech, D, Grond, S, et al. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage, 1992; 7: 259–266.CrossRefGoogle ScholarPubMed
Aronoff, G M. Opioids in chronic pain management: Is there a significant risk of addiction?Curr Rev Pain, 2000; 4: 112–121.CrossRefGoogle Scholar
Management of chronic pain syndromes: Issues and interventions. Pain Med, 2005; 6: S1–S21.CrossRef
Caraceni, A, Zecca, E, Bonezzi, C, et al. Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol, 2004; 22: 2909–2917.CrossRefGoogle ScholarPubMed
McDonald, A A and Portenoy, R K. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Supp Oncol, 2006; 4: 43–52.Google ScholarPubMed
Hanks, G W. The pharmacological treatment of bone pain. Cancer Surv, 1988; 7: 87–101.Google ScholarPubMed
Pinski, J and Dorff, T B. Prostate cancer metastases to bone: Pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer, 2005; 41: 932–940.CrossRefGoogle ScholarPubMed
Finlay, I G, Mason, M D, and Shelley, M. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol, 2005; 6: 392–400.CrossRefGoogle ScholarPubMed
Posteraro, A F, Dupuy, D E, and Mayo–Smith, W W. Radiofrequency ablation of bony metastatic disease. Clin Radiol, 2004; 59: 803–811.CrossRefGoogle ScholarPubMed
Hacein-Bey, L, Baisden, J L, Lemke, D M, et al. Treating osteoporotic and neoplastic vertebral compression fractures with vertebroplasty and kyphoplasty. J Palliat Med, 2005; 8: 931–938.CrossRefGoogle ScholarPubMed
Callstrom, M R and Charboneau, J W. Percutaneous ablation: Safe, effective treatment of bone tumors. Oncology, 2005; 19(Suppl 4): S22–S26.Google ScholarPubMed
Posteraro, A F, Dupuy, D E, and Mayo-Smith, W W. Radiofrequency ablation of bony metastatic disease. Clin Radiol, 2004; 59: 803–811.CrossRefGoogle ScholarPubMed
Elkersh, M A, Simopoulos, T T, and Bajwa, Z H. Fundamentals of interventional pain medicine. The Neurol, 2005; 11: 285–293.CrossRefGoogle ScholarPubMed
Wong, G Y, Schroeder, D R, and Carns, P E. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. A randomized controlled trial. JAMA, 2004; 291: 1092–1099.CrossRefGoogle ScholarPubMed
Davis, M P and Walsh, D. Treatment of nausea and vomiting in advanced cancer. Support Care Cancer, 2000; 8: 444–452.CrossRefGoogle ScholarPubMed
Boer-Dennert, M, Wit, R, Schmitz, P I, et al. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br J Cancer, 1997; 76: 1055–61.CrossRefGoogle ScholarPubMed
Aapro, M. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology, 2005; 69: 97–109.CrossRefGoogle ScholarPubMed
Olver, I N. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J, 2005; 35: 478–481.CrossRefGoogle ScholarPubMed
Hesketh, P J, Grunberg, S M, Gralla, R J, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol, 2003; 21: 4077–4080.CrossRefGoogle ScholarPubMed
Herrstedt, J, Muss, H B, Warr, D G, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer, 2005; 104: 1548–1555.CrossRefGoogle ScholarPubMed
Campora, E, Merlini, L, Bruzzone, M, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage, 1991; 6: 428–430.CrossRefGoogle ScholarPubMed
Hardy, J, Daly, S, McQuade, B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer, 2002; 10: 231–236.CrossRefGoogle Scholar
Chung, F, Lane, R, Spraggs, C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol, 1999; 16:669–677.CrossRefGoogle ScholarPubMed
Glare, P, Pereira, G, Kristjanson, L J, et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supp Care Cancer, 2004; 12: 432–440.CrossRefGoogle ScholarPubMed
Bruera, E, Seifert, L, Watanabe, S, et al. Chronic nausea in advanced cancer patients: A retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage, 1996; 11: 147–153.CrossRefGoogle ScholarPubMed
Mystakidou, K, Befon, S, Liossi, C, et al. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer, 1998; 83: 1214–1243.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
Sorbe, B G, Hobgerg, T, Glimelius, B, et al. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer, 1994; 73: 445–454.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Critchley, P, Plach, N, Grantham, M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: A systematic review. J Pain Symptom Manage, 2001; 22: 631–634.CrossRefGoogle ScholarPubMed
Passik, S D, Lundbert, J, and Kirsh, K L. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 2002; 23: 526–532.CrossRefGoogle ScholarPubMed
Passik, S D, Kirsh, K L, Theobald, D E, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage, 2003; 25: 485–488.CrossRefGoogle ScholarPubMed
Navari, R M, Einhorn, L H, Passik, S D, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Supp Care Cancer, 2005; 13: 529–534.CrossRefGoogle ScholarPubMed
Currow, D C, Coughlan, M, Fardell, B, et al. Use of ondansetron in palliative medicine. J Pain Symptom Manage, 1997; 13: 302–307.CrossRefGoogle ScholarPubMed
Tramer, M R, Carroll, D, Campbell, F A, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ, 2001; 323: 1–8.CrossRefGoogle ScholarPubMed
Walsh, D, Nelson, K A, and Mahmoud, F A. Established and potential therapeutic applications of cannabinoids in oncology. Supp Care Cancer, 2003; 11: 137–143.Google Scholar
Malik, I A, Khan, W A, Qazilbash, M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin: A prospective randomized trial. Am J Clin Oncol, 1995; 18: 170–175.Google ScholarPubMed
Ezzo, J, Vickers, A, Richardson, M A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol, 2005; 23: 7188–7198.CrossRefGoogle ScholarPubMed
Roscoe, J A, Morrow, G R, Hickok, J T, et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage, 2003; 26: 731–742.CrossRefGoogle ScholarPubMed
Mancini, I and Bruera, E. Constipation in advanced cancer patients. Supp Care Cancer, 1998; 6: 356–364.CrossRefGoogle ScholarPubMed
Homsi, J, Walsh, D, Rivera, N, et al. Symptom evaluation in palliative medicine: Patients report vs systematic assessment. Supp Care Cancer, 2006; 14: 444–453.CrossRefGoogle ScholarPubMed
Fallon, M and Neill, B. ABC of palliative care: Constipation and diarrhoea. BMJ, 1997; 315: 1293–1296.CrossRefGoogle ScholarPubMed
Tamayo, A C and Diaz-Zuluaga, P A. Management of opioid-induced bowel dysfunction in cancer patients. Supp Care Cancer, 2004; 12: 613–618.Google ScholarPubMed
Allan, L, Richarz, U, Simpson, K, et al. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine, 2005; 30: 2484–2490.CrossRefGoogle ScholarPubMed
Muller-Lissner, S A, Kamm, M A, Scarpignato, C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol, 2005; 100: 232–242.CrossRefGoogle ScholarPubMed
Meissner, W, Schmidt, U, Hartmann, M, et al. Oral naloxone reverses opioid-associated constipation. Pain, 2000; 84: 105–109.CrossRefGoogle ScholarPubMed
Sykes, N P. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med, 1996; 10: 135–44.CrossRefGoogle ScholarPubMed
Cherny, N I. Taking care of the terminally ill cancer patient: Management of gastrointestinal symptoms in patients with advanced cancer. Ann Oncol, 2004; 15: S205–S213.Google ScholarPubMed
Cascinu, S. Management of diarrhea induced by tumors or cancer therapy. Curr Opinion Oncol, 1995; 7: 325–329.CrossRefGoogle ScholarPubMed
Ippoliti, C. Antidiarrhea agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm, 1998; 55: 1573–1580.Google ScholarPubMed
Yavuzsen, T, Davis, M P, Walsh, D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol, 2005; 23: 8500–8511.CrossRefGoogle ScholarPubMed
Body, J J. The syndrome of anorexia-cachexia. Curr Opin Oncol, 1999; 11: 225–260.CrossRefGoogle ScholarPubMed
MacDonald, N. Is there evidence for earlier intervention in cancer-associated weight loss?J Supp Oncol, 2003; 1: 279–286.Google ScholarPubMed
Wilcock, A. Anorexia: A taste of things to come?Palliat Med, 2006; 20: 43–45.CrossRefGoogle ScholarPubMed
Simons, J P, Schols, A M, Hoefnagels, J M, et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: A randomized, placebo-controlled trial. Cancer, 1998; 82: 553–560.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Desport, J C, Gory-Delabaere, G, Blanc-Vincent, M P, et al. Standards, options, and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer, 2003; 89: S98–S100.CrossRefGoogle Scholar
Sood, A, Moynihan, T J. Cancer-related fatigue: An update. Curr Oncol Rep, 2005; 7: 277–282.CrossRefGoogle ScholarPubMed
Raison, C L and Miller, A H. Depression in cancer: New developments regarding diagnosis and treatment. Biol Psychiat 2003; 54: 283–294.CrossRefGoogle ScholarPubMed
Hickok, J T, Roscoe, J A, Morrow, G R, et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer, 2005; 104: 1772–1778.CrossRefGoogle ScholarPubMed
Ahlberg, K, Ekman, T, Gaston-Johansson, F, et al. Assessment and management of cancer–related fatigue in adults. Lancet, 2003; 362: 640–650.CrossRefGoogle ScholarPubMed
Adamsen, L, Midtgaard, J, and Andersen, C, et al. Transforming the nature of fatigue through exercise: Qualitative findings from a multidimensional exercise programme in cancer patients undergoing chemotherapy. Eur J Cancer Care, 2004; 13: 362–370.CrossRefGoogle ScholarPubMed
Glaspy, J. Anemia and fatigue in cancer patients. Cancer, 2001; 92: S1719–S1724.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
Patrick, D, Gagnon, D D, Zagari, M J, et al. Assessing the clinical significance of health-related quality of life (HRQoL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer, 2003; 39: 335–345.CrossRefGoogle ScholarPubMed
Mock, V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monograph, 2004; 32: 112–118.CrossRefGoogle Scholar
Smith, R E. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival. J Supp Oncol, 2003; 1: 249–258.Google ScholarPubMed
Munch, T N, Zhang, T, Wiley, J, et al. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med, 2005; 8: 1144–1149.CrossRefGoogle ScholarPubMed
Monti, M, Castellani, L, Berlusconi, A, et al. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage, 1996; 12: 18–22.CrossRefGoogle ScholarPubMed
Bruera, E, Driver, L, and Barnes, E A. Patient–controlled methylphenidate for the management of fatigue in patients with advancer cancer: A preliminary report. J Clin Oncol, 2003; 21: 4439–4443.CrossRefGoogle Scholar
Schwartz, A L, Mori, M, Gao, R, et al. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc, 2001; 33: 718–723.CrossRefGoogle ScholarPubMed
Dimeo, F C, Stieglitz, R D, Novelli-Fischer, U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer, 1999; 85: 2273–2277.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Iop, A, Manfredi, A M, and Bonura S, . Fatigue in cancer patients receiving chemotherapy: An analysis of published studies. Ann Oncol, 2004; 15: 712–720.CrossRefGoogle ScholarPubMed
Covey, A M. Management of malignant pleural effusions and ascites. J Supp Oncol, 2005; 3: 169–176.Google ScholarPubMed
Garrison, R N, Kaelin, L D, Galloway, R H, et al. Malignant ascites. Clinical and experimental observations. Ann Surg, 1986; 203: 644–651.Google ScholarPubMed
Runyon, B A, Hoefs, J C, and Morgan, T R. Ascitic fluid analysis in malignancy–related ascites. Hepatol, 1988; 8: 1104–1109.CrossRefGoogle ScholarPubMed
Gines, P, Cardenas, A, Arroyo, V, et al. Management of cirrhosis and ascites. N Engl J Med, 2004; 350: 1646–1654.CrossRefGoogle ScholarPubMed
Lee, C W, Bociek, G, and Faught, W. A survey of practice in management of malignant ascites. J Pain Symptom Manage, 1998; 16: 96–101.CrossRefGoogle ScholarPubMed
Saravanan, R and Cramp, M E. Investigation and treatment of ascites. Clin Med, 2002; 2: 310–313.CrossRefGoogle ScholarPubMed
Marrero, J, Martinez, F J, and Hyzy, R. Advances in critical care hepatology. Am J Respir Crit Care Med, 2003; 168: 1421–1426.CrossRefGoogle ScholarPubMed
Lidstone, V and Thorns A, . Pruritus in cancer patients. Cancer Treat Rev, 2001; 27: 305–312.CrossRefGoogle ScholarPubMed
Lugon, J R. Uremic pruritus: A review. Hemodial Intl, 2005; 9: 180–188.CrossRefGoogle ScholarPubMed
Zylicz, Z, Kragnik, M, Sorge, A A, et al. Paroxetine in the treatment of severe non-dermatological pruritus: A randomized, controlled trial. J Pain Symptom Manage, 2003; 26: 1105–1112.CrossRefGoogle ScholarPubMed
Prommer, E. Re: pruritus in patients with advanced cancer. J Pain Symptom Manage, 2005; 30: 201–202.CrossRefGoogle ScholarPubMed
Twycross, R, Greaves, M W, Handwerker, H, et al. Itch: Scratching more than the surface. Q J Med, 2003; 96: 7–26.CrossRefGoogle Scholar
Bosonnet, L. Pruritus: scratching the surface. Eur J Cancer Care. 2003; 12: 162–165.CrossRefGoogle Scholar
Krajnik, M and Zylicz, Z. Understanding pruritus in systemic disease. J Pain Symptom Manage, 2001; 21: 151–168.CrossRefGoogle ScholarPubMed
Price, T J, Patterson, W K, and Olver, I N. Rifampicin as treatment for pruritus in malignant cholestasis. Supp Care Cancer, 1988; 6: 533–535.CrossRefGoogle Scholar
Terg, R, Coronel, E, Sorda, J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717–722.CrossRefGoogle ScholarPubMed
Prieto, L N. The use of midazolam to treat itching in a terminally ill patients with biliary obstruction. J Pain Symptom Manage, 2004; 28: 531–532.CrossRefGoogle Scholar
Villamil, A G, Bandi, J C, Galdame, O A, et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver disease. Am J Med, 2005; 118: 1160–1163.CrossRefGoogle Scholar
Porzio, G, Aielli, F, Narducci, F, et al. Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. Supp Care Cancer, 2004; 12: 208–209.CrossRefGoogle Scholar
Friedman, J D and Dello Buono, F A. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacol, 2001; 35: 85–91.CrossRefGoogle ScholarPubMed
Aass, N, Fossa, S D, Dahl, A A, et al. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer, 1997; 33: 1597–604.CrossRefGoogle ScholarPubMed
Pirl, W F. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monograph, 2004; 32: 32–39.CrossRefGoogle Scholar
Stiefel, F, Trill, M D, Berney, A, et al. Depression in palliative care: A pragmatic report from the Expert Working Group of the European Association for Palliative Care. Supp Care Cancer, 2001; 9: 477–488.CrossRefGoogle Scholar
Ebmeier, K P, Donaghey, C, and Steel, J D. Recent developments and current controversies in depression. Lancet, 2006; 367: 153–167.CrossRefGoogle ScholarPubMed
Goodwin, J S, Zhang, D D, and Ostir, G V. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc, 2004; 52: 106–111.CrossRefGoogle ScholarPubMed
Hjerl, K, Andersen, E W, Keiding, N, et al. Depression as a prognostic factor for breast cancer mortality. Psychosomat, 2003; 44: 24–30.CrossRefGoogle ScholarPubMed
Passik, S D, Dugan, W, McDonald, M V, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol, 1998; 16: 1594–1600.CrossRefGoogle ScholarPubMed
Periyakoil, V J. Fast facts and concepts #43; Is it grief or depression? Second edition. August 2005. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.Google Scholar
Chochinov, H M, Wilson, K G, Enns, M, et al. “Are you depressed?” Screening for depression in the terminally ill. Am J Psychiatry, 1997; 154: 674–676.Google ScholarPubMed
Arnold, R A. Fast fact and concept #146; Screening for depression in palliative care. December 2005. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.Google Scholar
Holland, J C, Morrow, G R, Schmale, A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol, 1991; 9: 1004–1011.CrossRefGoogle ScholarPubMed
Sheard, T and Maguire, P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999; 80: 1770–1780.CrossRefGoogle ScholarPubMed
Thase, M E, Greenhouse, J B, Frank, E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry, 1997; 54: 1009–15.CrossRefGoogle ScholarPubMed
Clark, D B, Andrus, M R, and Byrd, D C. Drug interactions between linezolid and selective serotonin reuptake inhibitors: Case report involving sertraline and review of the literature. Pharmacotherapy, 2006; 25: 269–276.CrossRefGoogle Scholar
Weinrieb, R M, Auriacombe, M, Lynch, K G, et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Safety, 2005; 4: 337–344.CrossRefGoogle ScholarPubMed
Kroenke, K, Messina, N, Benattia, I, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry, 2006; 67: 72–80.CrossRefGoogle ScholarPubMed
Raskin, J, Pritchett, Y L, Wang, F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med, 2005; 6: 346–356.CrossRefGoogle ScholarPubMed
Theobald, D E, Kirsh, K L, Holtsclaw, E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage, 2002; 23: 442–447.CrossRefGoogle ScholarPubMed
Pereira, J and Bruera, E. Depression with psychomotor retardation: Diagnostic challenges and the use of psychostimulants. J Palliat Med, 2001; 4: 15–21.CrossRefGoogle ScholarPubMed
Burgess, C, Cornelius, V, Love, S, et al. Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ, 2005; 330: 702.CrossRefGoogle ScholarPubMed
Hipkins, J, Whitworth, M, Tarrier, N, et al. Social support, anxiety and depression after chemotherapy for ovarian cancer: A prospective study. Br J Health Psychol, 2004; 9: 569–581.CrossRefGoogle ScholarPubMed
Fowler, J M, Carpenter, K M, Gupta, P, et al. The gynecologic oncology consult: Symptom presentation and concurrent symptoms of depression and anxiety. Obstet Gynecol, 2004; 103: 1211–1217.CrossRefGoogle ScholarPubMed
Fellowes, D, Barnes, K, and Wilkinson, S. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database Syst Rev, 2004; (2): CD002287.Google ScholarPubMed
Sloman, R. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs, 2002; 25: 432–435.CrossRefGoogle ScholarPubMed
Bottomley, A. Anxiety and the adult cancer patient. Eur J Cancer Care, 1998; 7: 217–224.CrossRefGoogle ScholarPubMed
Goodman, W K. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry, 2004; 65: S8–S13.Google ScholarPubMed
Graci, G. Pathogenesis and management of cancer-related insomnia. J Supp Oncol, 2005; 3: 349–359.Google ScholarPubMed
Theobald, D E. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone, 2004; 6: S15–S21.CrossRefGoogle ScholarPubMed
Miller, M and Arnold, R M. Fast facts and concepts #101; Insomnia: Patient assessment. November 2003. End-of-life Physician Education Resource Center. www.eperc.mcw.edu.
Miller, M and Arnold, R M. Fast facts and concepts #104: Non-pharmacologic therapy for insomnia. January 2004. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×